Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta‐Analysis of 26 Studies Involving more than 20,000 Participants

Abstract

Our meta-analyses suggested a possible indication of relationship between Helicobacter pylori infection and the risk of myocardial infarction. The pathogenicity might not be affected by age and race. More researches should be conducted to explore the mechanisms involved.

The relationship betweenHelicobacter pyloriseropositivity and COPD

“…Additionally, previous studies have shown that those with H. pylori seropositivity are at an increased risk of myocardial infarction or coronary heart disease 19 20. Consistent with these prior observations, we found that those with H. pylori seropositivity had an increased risk of cardiovascular death, albeit at a borderline statistical significance (table 2).…”

“…Our data support the hypothesis that H. pylori could contribute to systemic inflammation in COPD19 by showing that CRP was elevated in the seropositive group (table 1). Additionally, previous studies have shown that those with H. pylori seropositivity are at an increased risk of myocardial infarction or coronary heart disease 19 20.…”

Helicobacter pylori infection and extragastroduodenal diseases

“…Недавний крупный метаанализ J. Liu и соавт. [27], объединивший 26 исследований случай-контроль, продемонстрировал, что инфекция H. pylori ассоциирована с повышенным риском развития инфаркта мио-карда (ОШ 2,10 при 95% ДИ от 1,75 до 2,53; р=0,06). С учетом того, что ДНК H. pylori нередко определяется в атеросклеротиче-ских бляшках, существует гипотеза, что данный микроорганизм может участвовать в процессе атеросклероза, однако доказатель-ных данных в этом направлении пока недостаточно [28].…”

Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?

“…6 HP is also associated with gastrointestinal non-malignant diseases, such as functional dyspepsia, 7 gastritis and peptic ulcer disease, 8 as well as with iron-deficient anemia, 9 idiopathic thrombocytopenic purpura 10 and risk of cardiovascular events. 11 In fact, it has been demonstrated that HP eradication not only improves most non-malignant associated diseases, but may also reduce the future risk of gastric cancer by up to 80%, 12 and a recent meta-analysis suggests that population screening and eradication of HP strategy is cost-effective. 13 According to the Maastricht IV Consensus on HP management, 1 clarithromycin resistance in each region should determine the most adequate first-line treatment for HP eradication -in regions where the clarithromycin resistance is inferior to 15% -20%, the triple therapy (TT), containing a proton-pump inhibitor (PPI), amoxicillin and clarithromycin, is adequate, whereas if the resistance to clarithromycin is superior to this threshold, other treatment options, such as the sequential treatment (ST) (PPI plus amoxicillin followed by PPI, clarithromycin and an imidazole) could be preferable.…”